口服P2Y抑制剂的比较综述
Comparative Review of Oral P2Y Inhibitors.
作者信息
Koski Renee, Kennedy Blake
出版信息
P T. 2018 Jun;43(6):352-357.
Abstract
Current practice guidelines recommend dual antiplatelet therapy comprised of aspirin and a purinergic signaling receptor Y (P2Y) for patients following acute coronary syndrome. This article compares the efficacy, safety, and other characteristics of the three available oral P2Y inhibitors-clopidogrel, prasugrel, and ticagrelor.
摘要
目前的临床实践指南建议，急性冠状动脉综合征患者应接受由阿司匹林和嘌呤能信号受体Y（P2Y）组成的双联抗血小板治疗。本文比较了三种可用的口服P2Y抑制剂（氯吡格雷、普拉格雷和替格瑞洛）的疗效、安全性及其他特性。
相似文献
1
Comparative Review of Oral P2Y Inhibitors.口服P2Y抑制剂的比较综述
P T. 2018 Jun;43(6):352-357.
2
Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.急性冠状动脉综合征患者口服P2Y12抑制剂相对疗效与安全性的Meta分析
Am J Cardiol. 2017 Jun 1;119(11):1723-1728. doi: 10.1016/j.amjcard.2017.03.011. Epub 2017 Mar 16.
3
Efficacy and Safety of Potent Oral P2Y Inhibitors in Medically Managed ACS Patients: a Meta-analysis.强效口服 P2Y 抑制剂在药物管理的 ACS 患者中的疗效和安全性：一项荟萃分析。
Cardiovasc Drugs Ther. 2020 Apr;34(2):199-208. doi: 10.1007/s10557-020-06940-y.
4
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.用于治疗急性冠状动脉综合征的口服抗血小板药物的进展：氯吡格雷、普拉格雷和替格瑞洛。
J Pharm Pract. 2016 Jun;29(3):239-49. doi: 10.1177/0897190014568383. Epub 2015 Feb 8.
5
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.急性冠状动脉综合征患者血小板P2Y12抑制的演变模式。
Platelets. 2014;25(6):416-22. doi: 10.3109/09537104.2013.836175. Epub 2013 Oct 10.
6
Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.新型 P2Y12 抑制剂的特点：临床实践中 P2Y12 抑制剂的选择。
J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S22-30. doi: 10.2459/JCM.0b013e328364bb18.
7
High and low on-treatment platelet reactivity to P2Y inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention.在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者当代队列中，P2Y 抑制剂的高反应性和低反应性。
Thromb Res. 2019 Mar;175:95-101. doi: 10.1016/j.thromres.2019.01.021. Epub 2019 Jan 31.
8
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.2008-2016 年经皮冠状动脉介入治疗后抗血小板药物初治患者中血小板二磷酸腺苷 P2Y12 受体抑制剂的使用和依从性趋势。
JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783.
9
Trends for and Clinical Factors Associated with Choice of Oral P2Y Inhibitors for Patients on Chronic Dialysis.慢性透析患者口服 P2Y 抑制剂选择的趋势及相关临床因素。
Cardiovasc Drugs Ther. 2019 Oct;33(5):511-521. doi: 10.1007/s10557-019-06913-w.
10
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.体外自体和体内血小板输注逆转氯吡格雷、普拉格雷和替格瑞洛对P2Y12抑制作用的疗效：APTITUDE研究
Circ Cardiovasc Interv. 2015 Nov;8(11):e002786. doi: 10.1161/CIRCINTERVENTIONS.115.002786.
引用本文的文献
1
Cryo-EM structures of the human P2X1 receptor reveal subtype-specific architecture and antagonism by supramolecular ligand-binding.人类 P2X1 受体的冷冻电镜结构揭示了亚型特异性结构和超分子配体结合的拮抗作用。
Nat Commun. 2024 Oct 1;15(1):8490. doi: 10.1038/s41467-024-52636-4.
2
Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018.美国血运重建术后 P2Y12 抑制剂的处方模式：2013-2018 年。
Clin Transl Sci. 2023 Oct;16(10):1886-1897. doi: 10.1111/cts.13596. Epub 2023 Aug 3.
3
Species Differences in Platelet Protease-Activated Receptors.血小板蛋白酶激活受体的种属差异。
Int J Mol Sci. 2023 May 5;24(9):8298. doi: 10.3390/ijms24098298.
4
Feasibility of Community Pharmacist-Initiated and Point-of-Care Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors.社区药师主导的基于基因型的即时降阶梯治疗口服 P2Y12 抑制剂的可行性。
Genes (Basel). 2023 Feb 25;14(3):578. doi: 10.3390/genes14030578.
5
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.P2Y12 抑制剂氯吡格雷通过阻断巨噬细胞向肌成纤维细胞转化来抑制肾纤维化。
Mol Ther. 2022 Sep 7;30(9):3017-3033. doi: 10.1016/j.ymthe.2022.06.019. Epub 2022 Jul 5.
6
The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.嘌呤能信号在抗包括 SARS-CoV-2 在内的病毒方面的潜力。
Front Immunol. 2022 Jun 17;13:904419. doi: 10.3389/fimmu.2022.904419. eCollection 2022.
7
Novel Thienopyrimidine-Based PET Tracers for P2Y Receptor Imaging in the Brain.新型噻吩并嘧啶基 PET 示踪剂用于脑内 P2Y 受体成像。
ACS Chem Neurosci. 2021 Dec 1;12(23):4465-4474. doi: 10.1021/acschemneuro.1c00641. Epub 2021 Nov 10.
8
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.替格瑞洛 60mg 用于既往心肌梗死患者的延长双联抗血小板治疗：多国家观察性研究 ALETHEIA 的设计。
Clin Cardiol. 2021 Oct;44(10):1333-1343. doi: 10.1002/clc.23702. Epub 2021 Aug 8.
9
Phosphorylation of protein kinase Cδ Tyr311 positively regulates thromboxane generation in platelets.蛋白激酶 Cδ Tyr311 的磷酸化正向调节血小板中血栓素的生成。
J Biol Chem. 2021 Jan-Jun;296:100720. doi: 10.1016/j.jbc.2021.100720. Epub 2021 Apr 28.
10
Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.新型冠状病毒病病理生理学中的炎症与血栓形成：蛋白水解酶激活和嘌呤能受体作为驱动因素和候选治疗靶点。
Physiol Rev. 2021 Apr 1;101(2):545-567. doi: 10.1152/physrev.00035.2020. Epub 2020 Oct 30.
本文引用的文献
1
International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies.国际血小板 P2Y 受体抑制剂转换治疗专家共识。
Circulation. 2017 Nov 14;136(20):1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164. Epub 2017 Oct 30.
2
The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention: A meta-analysis.经皮冠状动脉介入治疗术后患者口服抗凝剂联合与单一抗血小板治疗的安全性和有效性：一项荟萃分析。
Medicine (Baltimore). 2017 Sep;96(37):e8015. doi: 10.1097/MD.0000000000008015.
3
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.经皮冠状动脉介入治疗的急性冠状动脉综合征患者的抗血小板治疗降级指导（TROPICAL-ACS）：一项随机、开放标签、多中心试验。
Lancet. 2017 Oct 14;390(10104):1747-1757. doi: 10.1016/S0140-6736(17)32155-4. Epub 2017 Aug 28.
4
Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin.与华法林相比，直接口服抗凝剂三联疗法和双联疗法的疗效与安全性
Int Heart J. 2017 Aug 3;58(4):570-576. doi: 10.1536/ihj.16-381. Epub 2017 Jul 13.
5
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.急性冠脉综合征后转换双联抗血小板治疗的获益：TOPIC（急性冠脉综合征后血小板抑制的时机）随机研究。
Eur Heart J. 2017 Nov 1;38(41):3070-3078. doi: 10.1093/eurheartj/ehx175.
6
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery.经皮冠状动脉介入治疗（PCI）术后行非心脏手术患者的抗血小板治疗/双联抗血小板治疗（DAPT）。
J Am Coll Cardiol. 2017 Apr 11;69(14):1861-1870. doi: 10.1016/j.jacc.2017.02.012.
7
Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).冠状动脉血管成形术后，氯吡格雷与质子泵抑制剂联合使用是否仍与不良心血管结局增加相关？：对近期发表的研究（2012 - 2016年）的系统评价和荟萃分析
BMC Cardiovasc Disord. 2017 Jan 5;17(1):3. doi: 10.1186/s12872-016-0453-6.
8
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.经皮冠状动脉介入治疗（PCI）的房颤患者的出血预防。
N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.
9
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.RE-DUAL PCI试验的设计与原理：一项前瞻性、随机、3b期研究，比较达比加群酯双联抗栓治疗与华法林三联治疗在接受经皮冠状动脉介入治疗并置入支架的非瓣膜性心房颤动患者中的安全性和有效性。
Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572. Epub 2016 Aug 26.
10
Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.长期使用双重抗血小板治疗进行动脉粥样硬化血栓形成事件的二级预防：随机对照试验的荟萃分析。
Cardiovasc Revasc Med. 2017 Jan-Feb;18(1):10-15. doi: 10.1016/j.carrev.2016.07.006. Epub 2016 Jul 20.
Zotero 插件